Nettet19. des. 2024 · Last month, Benchmark analyst Aydin Huseynov wrote that Intellia Therapeutics ( NTLA) and Alnylam ( ALNY) could be potential Regeneron (NASDAQ: REGN) targets, adding that ALNY would likely... NettetCAMBRIDGE, Mass. , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2024 financial
Intellia Therapeutics Inc. (NTLA): An Important Analyst Insights
Nettet1. Intellia Therapeutics Gene-editing specialist Intellia Therapeutics has admittedly been a stress-inducing investment over the past year as its share price is down about 45%. The company... Nettet1. mar. 2024 · Crispr Therapeutics AG has shed nearly two-thirds of its value since a recent peak in June. The company said Monday its programs will continue to advance and aren’t affected by the ruling. Investors appear to be valuing biotechnology companies as businesses rather than exciting ideas, and Intellia is no exception, said Brad Loncar, … brittany hager mcneely
These 7 Disruptive Technologies Could Be Worth Trillions …
Nettet15. apr. 2024 · In addition, the company has several licensing agreements with CRISPR Therapeutics, Abbott, and Microsoft. Intellia Therapeutics’ approach has received. … Nettet12 timer siden · Are you looking for some growth stocks than can double in value? Two stocks that analysts appear to be bullish on right now are Intellia Therapeutics (NTLA … Nettet21. nov. 2024 · Intellia Therapeutics is currently trading at 129.48 $ per share (November 19th) with a market cap of 9.64 bn$. The stock has been showing a strong price increase throughout the year, with ... caps playoffs tickets